ライフサイエンスコーパス: cutaneous

1 significantly with respect to sex, age, and cutaneous, abdominal, articular, or renal involvement.

2 e curves showed no HTN-related difference in cutaneous adrenergic sensitivity (logEC50 ; NTN: -7.4 +/

3 armustine doses but was associated with more cutaneous adverse events.

4 followed up to detect whether they developed cutaneous AE at the time HR was detected.

5 ioceptive deficits and noted no reduction in cutaneous afferent innervation or upregulation of the in

6 fy the functional organization of muscle and cutaneous afferent synapses onto immature rat lamina I s

7 vealed significant convergence of muscle and cutaneous afferent synaptic input onto individual projec

8 erception of headache and the development of cutaneous allodynia and central sensitization.

9 INTERPRETATION: Cutaneous amyloid was detected in 70% of TTR-FAP and 20%

10 contrasted with data generated using passive cutaneous anaphylaxis, ovalbumin-induced asthma and arth

11 t-, and dansyl-specific IgE-mediated passive cutaneous anaphylaxis; and attenuate dansyl IgE-mediated

12 h CD30-positive mycosis fungoides or primary cutaneous anaplastic large-cell lymphoma who had been pr

13 pressed in CD30+ anaplastic cells in primary cutaneous anaplastic T-cell lymphoma and large-cell tran

14 poptosis and G1 cell-cycle arrest in primary cutaneous anaplastic T-cell lymphoma cells in vitro and

15 Primary cutaneous anaplastic T-cell lymphoma, characterized by t

16 There were 4,352 cutaneous and 32,568 noncutaneous lymphomas.

17 of unknown cause, characterized by numerous cutaneous and internal venous malformations; gastrointes

18 d DNA viruses that preferentially infect the cutaneous and mucocutaneous epithelia of vertebrates.

19 use strains showed active infections at both cutaneous and mucosal sites.

20 human papillomavirus (HPV) infection across cutaneous and mucosal tissues within individuals has not

21 ansient exaggerated inflammatory response to cutaneous and peritoneal inflammatory stimuli.

22 play a negligible role in the elevations in cutaneous and serum inflammatory cytokines induced by ep

23 d eosinophilic esophagitis), suggesting both cutaneous and systemic immune activation.

24 These parasites apparently cause both cutaneous and visceral disease, and may have evolved a n

25 LC and iDDC process cutaneous antigens and migrate out of the skin and mucos

26 Nod2(-/-) pups, which then acquired altered cutaneous bacteria and delayed healing.

27 Cutaneous beta human papillomavirus (HPV) infection acro

28 stic carcinoma (ACC), and other salivary and cutaneous cancers, whose tumors were sequenced between J

29 duced skin damage ranges from photoaging and cutaneous carcinogenesis caused by UV exposure, to treat

30 and are active in primary cultures of human cutaneous cells.

31 Our work provides a high resolution view of cutaneous cellular gene expression and suggests that tra

32 aining immunohistochemistry to determine the cutaneous cellular source of CXCL9.

33 cell-derived IL-22 significantly exacerbates cutaneous chronic GVHD and that IL-22 is produced by hig

34 nterstitial lung disease and 3 patients with cutaneous clinical features similar to anti-MDA5 skin sy

35 idate for patients with peripheral (PTCL) or cutaneous (CTCL) T-cell lymphoma.

36 g mice leads not only to a rapid increase in cutaneous cytokine mRNA expression but also an increase

37 Vitiligo is the most common cutaneous depigmentation disorder worldwide, yet little

38 ophageal temperature probe and a noninvasive cutaneous device to monitor their core temperature conti

39 Clinical factors of cutaneous disease and other common diagnoses assessed in

40 Little is known about cutaneous disease and skin cancer risk in this OTR popul

41 To compare the incidence of cutaneous disease between white and nonwhite OTRs.

42 L. adleri has been associated with cutaneous disease in humans, but can be asymptomatic in

43 Prevalence and characteristics of cutaneous disease were compared in 154 white and 258 non

44 nting cell stimulation, and priming of overt cutaneous disease.

45 ells plays a crucial role in the severity of cutaneous disease.

46 reviously known ADRs for drugs prescribed to cutaneous diseases, and are also able to identify promis

47 ons for treating multiple moderate-to-severe cutaneous diseases.

48 which has implications for many inflammatory cutaneous diseases.

49 drugs that might interact with the drugs for cutaneous diseases.

50 Mosaicism is easily appreciated in cutaneous disorders, as phenotypically distinct mutant c

51 mine the microbiome in both healthy skin and cutaneous disorders, including acne, psoriasis, and atop

52 new mechanism of sensory modulation through cutaneous dopaminergic signalling.

53 e rate (OCRR) was defined as complete (final cutaneous ePOST score of 0 or 1) or partial response (eP

54 edema, 50 of anaphylaxis, 26 of nonimmediate cutaneous eruptions, and 17 of bronchospasm related to A

55 pending on the anatomical depth of S. aureus cutaneous exposure.

56 CD8(+)IL-13(+) cells play a critical role in cutaneous fibrosis, the most characteristic feature of s

57 Hannen et al. report that cutaneous glucocorticoidogenesis and expression of gluco

58 To demonstrate a functional ES-TUBB3 axis in cutaneous healing, we showed increased TUBB3(+) melanocy

59 ctrical stimulation (ES) is known to promote cutaneous healing; however, its ability to regulate rein

60 atory T cell migration to the skin to ensure cutaneous homeostasis.

61 could be explored for the refinement of the cutaneous homing of the therapeutic stem cells.

62 on of the stratum corneum and provide innate cutaneous host defense.

63 The cutaneous HSV-1 infection of mice results in the develop

64 Topical solenopsin derivatives normalized cutaneous hyperplasia in this model, decreased T cell in

65 ferents reduced both ongoing pain and evoked cutaneous hypersensitivity in the context of cystitis, b

66 Of the 381 SPT with reliable results, cutaneous hypersensitivity was found in 201 (53%) partic

67 n the skin can influence the behavior of the cutaneous immune system, but the mechanisms responsible

68 We assessed cutaneous immunity based on the extent of erythema and i

69 l proopiomelanocortin and glucocorticoids on cutaneous immunity contributes to inflammatory and autoi

70 s), which act as professional APC to control cutaneous immunity.

71 Ns-CIT represents a novel minimally invasive cutaneous immunotherapy to prevent the progression of Ov

72 Cutaneous implantation and systemic mycoses are neglecte

73 is is an emerging fungal pathogen that cause cutaneous infection and could cause death.

74 influence of mating type on the severity of cutaneous infection.

75 onal specialization of dermal macrophages in cutaneous infections have been little studied.

76 Previous studies have tested cutaneous infections in different immunocompromised and

77 This disorder is characterized by recurrent cutaneous infections, increased serum IgE levels, and se

78 We sought to characterize molecularly cutaneous inflammation and its correlation with clinical

79 /gamma are important therapeutic targets for cutaneous inflammation and suggest topical usage of inhi

80 on of TRPV1-positive sensory nerves promotes cutaneous inflammation in the SADBE-induced ACD.

81 and the etiology of this predisposition for cutaneous inflammation is unknown.

82 of recombinant TWEAK into naive mice induces cutaneous inflammation with histological and molecular s

83 abnormalities in epidermal function provoke cutaneous inflammation, and because intrinsically aged s

84 les in initiating, modulating, and resolving cutaneous inflammation.

85 in the imiquimod (IMQ)-driven mouse model of cutaneous inflammation.

86 itro-fatty acid, has the capacity to inhibit cutaneous inflammation.

87 ted a role for NLRP10 as a suppressor of the cutaneous inflammatory response to Leishmania major infe

88 We conclude that chronic cutaneous injury can lead to injury and dysfunction of t

89 After traumatic cutaneous inoculation, several fungi can cause neglected

90 ion of Ca(2+)-permeable AMPARs compared with cutaneous inputs.

91 pathway, have been characterized in primary cutaneous large B-cell lymphoma, leg type.

92 The treatment of cutaneous leishmaniasis (CL) caused by Leishmania brazil

93 a (Viannia) braziliensis can cause localized cutaneous leishmaniasis (LCL), which heals spontaneously

94 investigated the role of skin microbiota in cutaneous leishmaniasis and found that human patients in

95 ward Th2 responses, which are detrimental in cutaneous leishmaniasis but beneficial in acute schistos

96 rovide an alternate approach to treatment of cutaneous leishmaniasis caused by L (V) panamensis.

97 Cutaneous leishmaniasis due to Leishmania braziliensis i

98 We hypothesized that cutaneous leishmaniasis patients have increased expressi

99 NLRP3 protein in intermediate monocytes from cutaneous leishmaniasis patients.

100 s is an important etiological agent of human cutaneous leishmaniasis that accounts for more than 8% o

101 d Leishmania tropica, the causative agent of cutaneous Leishmaniasis with MCs were studied.

102 mononuclear cells (PBMCs) from patients with cutaneous leishmaniasis, CpG treatment similarly exhibit

103 the causative agents of trypanosomiasis, and cutaneous leishmaniasis, identifying several potent stru

104 or Leishmania major, which cause visceral or cutaneous leishmaniasis, respectively, elicited dramatic

105 ol the parasite load and alter the course of cutaneous leishmaniasis.

106 ssociated with increased pathology in murine cutaneous leishmaniasis.

107 an absence of ulceration and necrosis during cutaneous leishmaniasis.

108 Clinicopathologic correlation of cutaneous lesions and genetic studies in 11 members of a

109 relatives presenting with dermal hyperneury, cutaneous lesions classically described in MEN 2B syndro

110 jor Seidman [LmSd]) that produces nonhealing cutaneous lesions in conventionally resistant C57BL/6 mi

111 rely attenuated in their ability to generate cutaneous lesions in mice.

112 Identification of cutaneous lesions not previously described in patients w

113 The dermal infiltrate of cutaneous lesions of histiocytoid Sweet syndrome is comp

114 Cutaneous lesions were histopathologically and immunohis

115 Cutaneous lupus erythematosus is a disfiguring and commo

116 Evaluation of discoid and subacute cutaneous lupus erythematosus lesions showed significant

117 he mechanism for its increased production in cutaneous lupus erythematosus.

118 tomic overlap with inflammatory processes in cutaneous lupus.

119 , and CD44 (rendering the E-selectin ligands cutaneous lymphocyte Ag, CD43E, and hematopoietic cell E

120 We previously showed that cutaneous lymphocyte-associated antigen (CLA), a functio

121 with the macerated stillborn showing diffuse cutaneous maculopapillary skin lesions involving the hea

122 ion, which contributes to the development of cutaneous malignancies.

123 Known high-risk cutaneous malignant melanoma (CMM) genes account for mel

124 also showing multiple sclerotic fibromas, a cutaneous manifestation of PTEN (phosphatase and tensin

125 To describe a family with cutaneous manifestations not previously described in pat

126 Cutaneous manifestations of MEN 2A syndrome include macu

127 otic fibromas should be added to the list of cutaneous manifestations of patients with the familial M

128 ptoms are due to the release of histamine by cutaneous mast cells, the underlying pathophysiology is

129 Organization (WHO) divides the disease into cutaneous mastocytosis, systemic mastocytosis, and local

130 rare cases, the development of an additional cutaneous MCC tumor is clinically consistent with a seco

131 A family history of cutaneous melanoma ('melanoma') is a well-established ri

132 Genomic analyses of cutaneous melanoma (CM) have yielded biological and ther

133 Cutaneous melanoma (CM) is the most lethal skin cancer.

134 ed, phase 3 trial in patients with stage III cutaneous melanoma (excluding lymph node metastasis </=1

135 (n = 60 [28%]), mesothelioma (n = 48 [22%]), cutaneous melanoma (n = 38 [18%]), and renal cell carcin

136 studied the transcriptome landscape of skin cutaneous melanoma (SKCM) using 103 primary tumor sample

137 Despite remarkable progress in cutaneous melanoma genomic profiling, the mutational lan

138 l, eligible patients had surgically resected cutaneous melanoma in the following categories: (1) T2bN

139 Cutaneous melanoma is a type of cancer with an inherent

140 A well-defined risk factor and precursor for cutaneous melanoma is the dysplastic nevus.

141 Virus-specific CD8(+) TILs migrated into cutaneous melanoma lesions during acute infection with e

142 ne variants have also been found in familial cutaneous melanoma pedigrees, but their contribution to

143 dscape of coding and non-coding mutations in cutaneous melanoma resolved novel signatures of mutagene

144 Trametinib and Dabrafenib due to metastatic cutaneous melanoma stage IV.

145 ilimumab (n = 35, mucosal melanoma; n = 326, cutaneous melanoma).

146 enes included BRAF, CDKN2A, NRAS and TP53 in cutaneous melanoma, BRAF, NRAS and NF1 in acral melanoma

147 duce profound clinical responses in advanced cutaneous melanoma, but complete remissions are frustrat

148 For mucosal and cutaneous melanoma, respectively, the incidence of grade

149 therapies have shown efficacy in metastatic cutaneous melanoma, their use in ocular variants has bee

150 (95% CI, 5.1 to 7.5 months) for mucosal and cutaneous melanoma, with objective response rates of 23.

151 (95% CI, 8.9 to 16.7 months) for mucosal and cutaneous melanoma, with objective response rates of 37.

152 icted to be deleterious/damaging are rare in cutaneous melanoma.

153 (10%) had mucosal melanoma and 665 (75%) had cutaneous melanoma.

154 CDK4/6 pathway is frequently dysregulated in cutaneous melanoma.

155 nsitive and specific method for detection of cutaneous melanoma.

156 lectronic laboratory databases, and incident cutaneous melanomas (n = 14,056) were identified from an

157 lanoma, is proposed in cases with 2 invasive cutaneous melanomas and/or related cancers in the same p

158 that enrolled patients with incident primary cutaneous melanomas from population-based and hospital-b

159 croenvironment can suppress MCSC-originating cutaneous melanomas.

160 ith a second primary MCC tumor rather than a cutaneous metastasis, which has important treatment and

161 findings suggest a link between a dysbiotic cutaneous microbiome and HS.

162 Insight into the cutaneous microbiome in HS using next-generation sequenc

163 actors point to potential involvement of the cutaneous microbiome.

164 Furthermore, IL-23 modulated the cutaneous microenvironment by limiting regulatory T cell

165 assist in the diagnosis of abnormalities of cutaneous microstructure, and hence, aid in the determin

166 KEY POINTS: Age-related changes in cutaneous microvascular and cardiac functions limit the

167 ximally restrained by age-related changes in cutaneous microvascular and cardiac functions.

168 Cutaneous microvasculopathy complicates wound healing.

169 In this review, we discuss examples of cutaneous mosaicism, approaches to gene discovery in the

170 d skin biopsy was taken after 2-3 years, the cutaneous mRNA expression of GSTT2, CTSA, PPARG, CDA, EN

171 Stimulation of rat segmental dorsal cutaneous nerves (DCNs) evokes the nociceptive intersegm

172 Cutaneous nerves extend throughout the dermis and epider

173 Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma.

174 ell carcinoma (MCC) is a rare and aggressive cutaneous neuroendocrine neoplasm with a high risk of re

175 ts on the skin (neurogenic spots), caused by cutaneous neurogenic inflammation, in the dermatome that

176 e demonstrate that primary predisposition to cutaneous NVP HSR, seen across ancestral groups, can be

177 We excluded patients with cutaneous or non-severe systemic mastocytosis after a pr

178 c musculoskeletal pain compared with pain of cutaneous origin.

179 holine at the neuromuscular junction of frog cutaneous pectoris muscle.

180 -deficient mice (IL-17C+KO) and examined the cutaneous phenotype.

181 F1 phenotype with neither externally visible cutaneous/plexiform neurofibromas nor other tumors.

182 rs malabsorb vitamin D and thus must rely on cutaneous production of vitamin D3.

183 the role of ACKR2 in limiting the spread of cutaneous psoriasiform inflammation to sites that are re

184 dermatitis associated with radiotherapy, to cutaneous radiation syndrome, a frequently fatal consequ

185 maintenance were neutropenia (56% v 22%) and cutaneous reactions (5% v 1%), respectively.

186 by longitudinally reduced rMal d 1-specific cutaneous reactions (P = .022) and enhanced IgG4/IgE rat

187 eath included sepsis, malignancy, and severe cutaneous reactions with multiorgan failure.

188 That the cutaneous reflex amplitude in all muscles was similarly

189 f the present study was to determine whether cutaneous reflexes and their phase-dependent modulation

190 Cutaneous reflexes are important for responding rapidly

191 The speed-dependent modulation of cutaneous reflexes was assessed by evoking and character

192 rficial peroneal nerve electrically to evoke cutaneous reflexes.

193 pair, resulting in slowed axon regeneration, cutaneous reinnervation, and functional recovery.

194 Interestingly, the impaired cutaneous response of IL-1R1(-/-) mice did not reflect a

195 The overall cutaneous response rate (OCRR) was defined as complete (

196 In contrast, cutaneous responses to VZV antigen challenge were increa

197 ver, the mechanisms by which miR response to cutaneous S. aureus contributes to DFU pathophysiology a

198 efficacy and safety of anti-TNF in treating cutaneous sarcoidosis in a large observational study.

199 s factor alpha agents (anti-TNF) in treating cutaneous sarcoidosis is lacking.

200 311 is required for the production of normal cutaneous scars and place P311 immediately up-stream of

201 ociated with an increased risk of aggressive cutaneous SCC after retransplantation.

202 ry endpoint was the occurrence of aggressive cutaneous SCC after the second transplantation.

203 population and suggest a shared etiology for cutaneous SCC and other SCC in the setting of immunosupp

204 hese findings highlight the possibility that cutaneous SCC development, and perhaps BCC development,

205 Cutaneous SCC occurrence (n = 6,169) was associated with

206 Cutaneous SCC was also associated with increased risk of

207 ults suggest that transplant recipients with cutaneous SCC, but not BCC, have an increased risk of de

208 Risks were particularly elevated for non-cutaneous SCC, including those of the oral cavity/pharyn

209 ergic signalling contributes to differential cutaneous sensitivity in darker versus lighter pigmented

210 We show that thermal and mechanical cutaneous sensitivity is pigmentation dependent.

211 ing body of evidence that the combination of cutaneous sensitization via a disrupted skin barrier (ie

212 e to food allergens may be a risk factor for cutaneous sensitization.

213 ults suggest a comparable reliability of the cutaneous sensor using the zero-heat-flux method compare

214 vo functional imaging to identify a class of cutaneous sensory neurons that are selectively activated

215 The median cutaneous severity score was 5 and/or 6 at baseline.

216 mice harbored lower parasite burdens at the cutaneous site of inoculation compared with wild-type co

217 , B, and NK cells, showed minimal disease at cutaneous sites but developed persistent infection at th

218 melanoma is distinct from melanoma of other cutaneous sites, yet there is considerable variation wit

219 nal cord circuits that transmit and gate the cutaneous somatosensory modalities of touch, pain, and i

220 ations in multiple genes that are mutated in cutaneous squamous cell cancers.

221 Perineural invasion (PNI) in cutaneous squamous cell carcinoma (CSCC) has been associ

222 d that transformation of normal epidermis to cutaneous squamous cell carcinoma (cSCC) is causally lin

223 Cutaneous squamous cell carcinoma (cSCC) is one of the m

224 have identified genetic loci associated with cutaneous squamous cell carcinoma (cSCC) risk, but singl

225 nts (OTRs) have a 100-fold increased risk of cutaneous squamous cell carcinoma (cSCC).

226 in patients with inoperable locally advanced cutaneous squamous cell carcinoma (cSCC).

227 study included 53 patients with a history of cutaneous squamous cell carcinoma (SCC) after a first ki

228 r developing keratinocyte cancers, including cutaneous squamous cell carcinoma (SCC) and basal cell c

229 emporal trends in the risk of posttransplant cutaneous squamous cell carcinoma (SCC) are few and appe

230 f miRNA in epidermal development, psoriasis, cutaneous squamous cell carcinoma and re-epithelisation

231 t the development of UV irradiation-mediated cutaneous squamous cell carcinoma in mice.

232 l growth advantage on normal and neoplastic (cutaneous squamous cell carcinoma, cSCC) human epidermal

233 Nonmelanoma skin cancers, in particular cutaneous squamous cell carcinoma, have the highest stan

234 Actinic keratosis is a precursor to cutaneous squamous cell carcinoma.

235 Cetuximab was recently proposed for advanced cutaneous squamous cell carcinomas (cSCC); however, its

236 linical trial in which patients with diffuse cutaneous SSc were treated with C-82 or placebo on oppos

237 isotretinoin taken within 6 to 12 months of cutaneous surgery contributes to abnormal scarring or de

238 al dermabrasion, superficial chemical peels, cutaneous surgery, laser hair removal, and fractional ab

239 During MMS, unlike WLE, the entire cutaneous surgical margin is evaluated intraoperatively

240 based discussion regarding the known risk of cutaneous surgical procedures in the setting of systemic

241 DHCR7 encodes an enzyme important in cutaneous synthesis of vitamin D and DHCR7 mutations are

242 the serum proteome of patients with diffuse cutaneous systemic sclerosis and identified differential

243 clinical trials to assess changes in diffuse cutaneous systemic sclerosis skin disease over time.

244 atterns in the sera of patients with diffuse cutaneous systemic sclerosis.

245 ape and dynamics of active regulatory DNA in cutaneous T cell lymphoma (CTCL) by ATAC-seq.

246 ribe the chromatin accessibility profiles of cutaneous T cell lymphoma, with dynamic assessments of r

247 This review highlights the ability of these cutaneous T cells to regulate skin-specific environmenta

248 Cutaneous T-cell lymphoma (CTCL) is an incurable non-Hod

249 eripheral blood involvement in patients with cutaneous T-cell lymphoma (CTCL) portend a worse clinica

250 ies, compared to six healthy control and six cutaneous T-cell lymphoma (CTCL) samples from previously

251 roRNA (miRNA) dysregulation is a hallmark of cutaneous T-cell lymphoma (CTCL), an often-fatal maligna

252 Cutaneous T-cell lymphoma is a heterogeneous group of ly

253 ymphoma, angioimmunoblastic T-cell lymphoma, cutaneous T-cell lymphoma, adult T-cell leukemia/lymphom

254 hydroxamic acid is already approved to treat cutaneous T-cell lymphoma, it could potentially be used

255 ed 17 adults with stage IA through stage IIA cutaneous T-cell lymphoma, MF type, to evaluate treatmen

256 ith early stage (stage IA through stage IIA) cutaneous T-cell lymphoma, mycosis fungoides (MF) type,

257 s, comprises the second most common group of cutaneous T-cell lymphoma.

258 c T-cell lymphoma and large-cell transformed cutaneous T-cell lymphoma.

259 fungoides (MF) is the most frequent form of cutaneous T-cell lymphoma.

260 ly driven diseases, the malignant T cells of cutaneous T-cell lymphomas (CTCLs), such as Sezary syndr

261 Cutaneous T-cell lymphomas are rare, generally incurable

262 eviously treated patients with CD30-positive cutaneous T-cell lymphomas.

263 ges proinflammatory CC-chemokines, regulates cutaneous T-cell positioning, and limits the spread of i

264 peripheral TCL, 50% (n = 16) with 3 CR; and cutaneous TCL, 32% (n = 19).

265 compare accuracy of a continuous noninvasive cutaneous temperature using zero-heat-flux method to eso

266 We describe the cutaneous transcriptome of patients suffering a severely

267 In summary, we provide evidence that cutaneous transcripts in patients with CMT1A serve as di

268 We previously observed a cutaneous type IV immune response in nonhuman primates (

269 pertenue (TP) are major causative agents of cutaneous ulcer (CU) in the tropics.

270 larly impaired NF-kappaB activation, develop cutaneous ulceration from TNF exposure, and exhibit seve

271 n in HTN would be mediated by an increase in cutaneous vascular adrenergic sensitivity and a greater

272 (FVC, venous occlusion plethysmography) and cutaneous vascular conductance (CVC, laser-Doppler) were

273 eases in sympathetic outflow directed to the cutaneous vasculature and, correspondingly, greater redu

274 The cutaneous vasculature is involved in many diseases.

275 ure, sympathetically-mediated control of the cutaneous vasculature is not only preserved, but also ex

276 r-old patient with severe WAS manifesting as cutaneous vasculitis, inflammatory arthropathy, intermit

277 (i) whole-body cooling would elicit greater cutaneous vasoconstriction and greater increases in skin

278 adrenergic-dependent contributions to reflex cutaneous vasoconstriction and vascular adrenergic sensi

279 onse range for sympathetic reflex control of cutaneous vasoconstriction in HTN.

280 y older adults can achieve greater levels of cutaneous vasodilatation and cardiac output during passi

281 ed during passive heat stress, augments both cutaneous vasodilatation and cardiac output in healthy o

282 ABSTRACT: Primary ageing markedly attenuates cutaneous vasodilatation and the increase in cardiac out

283 ar and cardiac functions limit the extent of cutaneous vasodilatation and the increase in cardiac out

284 degrees C, P = 0.001 vs. controls) caused by cutaneous vasodilatation.

285 n older adults without parallel increases in cutaneous vasodilatation.

286 urons produced a profound hypothermia due to cutaneous vasodilatation.

287 c roles of IL-1 elements in host immunity to cutaneous viral infection remain elusive.

288 were less effective at protecting mice from cutaneous viral infection, and lung Fabp4/Fabp5 double-k

289 ngoing immunoglobulin replacement (14; 45%), cutaneous viral warts (7; 24%), short stature (4; 14%),

290 nuated global gene activation at the site of cutaneous VZV antigen challenge compared with young subj

291 lpha gene transfer significantly accelerated cutaneous wound healing in diabetic mice through facilit

292 Here, using an in vivo model of cutaneous wound healing in mice, we provide evidence tha

293 During the proliferative phase of cutaneous wound healing, dermal fibroblasts are recruite

294 In cutaneous wound healing, skin cells migrate from the wou

295 The cutaneous wound-healing program is a product of a comple

296 st, we show that ES treatment of human acute cutaneous wounds (n = 40) increased reinnervation.

297 pical application of erythropoietin (EPO) to cutaneous wounds in rats and mice with experimentally in

298 The healing of cutaneous wounds is dependent on the progression through

299 is preparation of PRP accelerates healing of cutaneous wounds only as a controlled release formulatio

300 sulting in impaired tumor clearance in a sub-cutaneous xenograft model.